ArticleAPL bioengineering2025
Regulation of airway remodeling in asthma: The synergistic effects of nanotechnology and Hippo pathway activation.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune and inflammatory mechanisms in asthma: insights into epigenetic modifications.Frontiers in immunology · 2025Pooled it
- The airway epithelial-immune axis: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a prevalent chronic respiratory condition characterized by airway remodeling, which contributes to irreversible airway narrowing and impaired lung function. Current therapies fail to effectively address this structural alteration. This study introduces an innovative strategy combining Quercetin, a natural flavonoid with anti-inflammatory and anti-proliferative properties, and chitosan-alginate nanoparticles (CA-NPs) to enhance bioavailability and therapeutic efficacy. By activating the Hippo signaling pathway, CA-NPs-Quercetin inhibits the proliferation and migration of human airway smooth muscle cells (HASMCs), key drivers of airway remodeling.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.